Humanigen的抗GM-CSF单抗Lenzilumab正在进行临床试验,评估是否可用于预防新冠病毒感染引起的细胞因子风暴

2020-03-10 MedSci原创 MedSci原创

Humanigen公司宣布正在对其抗人GM-CSF单克隆抗体lenzilumab进行临床试验,评估其是否可用于抑制或预防COVID-19新型冠状病毒感染引起的细胞因子风暴。

Humanigen公司宣布正在对其抗人GM-CSF单克隆抗体lenzilumab进行临床试验,评估其是否可用于抑制或预防COVID-19新型冠状病毒感染引起的细胞因子风暴。

最近预出版的文章"具有严重肺部综合症的新型冠状病毒感染患者中,GM-CSF + T细胞和CD14 + CD16 +单核细胞被异常激活(Aberrant pathogenic GM-CSF+ T cells and inflammatory CD14+CD16+ monocytes in severe pulmonary syndrome patients of a new coronavirus)",支持了以下假设:细胞因子风暴在冠状病毒感染引起的死亡中发挥重要的作用。

COVID-19冠状病毒可引起严重的肺损伤,需要在加护病房(ICU)进行护理和机械通气。这种肺损伤是由于过度激活的免疫反应引起细胞因子风暴所导致的。研究发现肺部损伤所导致的死亡与病毒本身没有直接关系,而是由于细胞因子风暴所导致。

Lenzilumab在动物模型中已显示可预防细胞因子风暴,并且这项工作已在同行评审的出版物中发表。预计很快将与Kite Pharma合作,对患者进行临床研究,以确定lenzilumab是否可以对CAR-T细胞治疗引起的细胞因子风暴发挥治疗作用。

原始出处:

https://www.firstwordpharma.com/node/1706892?tsid=4

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (8)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1668865, encodeId=bcf9166886515, content=<a href='/topic/show?id=a41d5339c1' target=_blank style='color:#2F92EE;'>#CSF#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5339, encryptionId=a41d5339c1, topicName=CSF)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7a5226466702, createdName=kcb078, createdTime=Sun Nov 01 00:56:39 CST 2020, time=2020-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1809611, encodeId=28821809611aa, content=<a href='/topic/show?id=6cd683e603b' target=_blank style='color:#2F92EE;'>#胞因子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83760, encryptionId=6cd683e603b, topicName=胞因子)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/017ED6AFEB45F49165298113DDC0656A/100, createdBy=84182500174, createdName=ms7019579240139182, createdTime=Sat Jan 30 00:56:39 CST 2021, time=2021-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1704968, encodeId=a89c1e04968e3, content=<a href='/topic/show?id=7af98121ae' target=_blank style='color:#2F92EE;'>#GM-CSF单抗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8121, encryptionId=7af98121ae, topicName=GM-CSF单抗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=50fa30912176, createdName=diushouji, createdTime=Sun Aug 30 19:56:39 CST 2020, time=2020-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1940438, encodeId=7ff9194043854, content=<a href='/topic/show?id=0de4919efc' target=_blank style='color:#2F92EE;'>#human#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9197, encryptionId=0de4919efc, topicName=human)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=674961, createdName=tamgche, createdTime=Wed Oct 28 21:56:39 CST 2020, time=2020-10-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1912318, encodeId=2b241912318d4, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11204, encryptionId=4de7112046c, topicName=mAb)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Sun Dec 06 09:56:39 CST 2020, time=2020-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1283645, encodeId=7a5c1283645cf, content=<a href='/topic/show?id=2c00e784416' target=_blank style='color:#2F92EE;'>#细胞因子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77844, encryptionId=2c00e784416, topicName=细胞因子)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0ad8182, createdName=axin009, createdTime=Thu Mar 12 02:56:39 CST 2020, time=2020-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1426395, encodeId=f3b21426395e4, content=<a href='/topic/show?id=032b948ec5' target=_blank style='color:#2F92EE;'>#IgE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9487, encryptionId=032b948ec5, topicName=IgE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0cff4064659, createdName=zhenjiu124, createdTime=Thu Mar 12 02:56:39 CST 2020, time=2020-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1027389, encodeId=7352102e38930, content=新冠肺炎,疫情何时才能消失, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=公卫新人, createdTime=Tue Mar 10 14:56:39 CST 2020, time=2020-03-10, status=1, ipAttribution=)]
    2020-11-01 kcb078
  2. [GetPortalCommentsPageByObjectIdResponse(id=1668865, encodeId=bcf9166886515, content=<a href='/topic/show?id=a41d5339c1' target=_blank style='color:#2F92EE;'>#CSF#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5339, encryptionId=a41d5339c1, topicName=CSF)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7a5226466702, createdName=kcb078, createdTime=Sun Nov 01 00:56:39 CST 2020, time=2020-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1809611, encodeId=28821809611aa, content=<a href='/topic/show?id=6cd683e603b' target=_blank style='color:#2F92EE;'>#胞因子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83760, encryptionId=6cd683e603b, topicName=胞因子)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/017ED6AFEB45F49165298113DDC0656A/100, createdBy=84182500174, createdName=ms7019579240139182, createdTime=Sat Jan 30 00:56:39 CST 2021, time=2021-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1704968, encodeId=a89c1e04968e3, content=<a href='/topic/show?id=7af98121ae' target=_blank style='color:#2F92EE;'>#GM-CSF单抗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8121, encryptionId=7af98121ae, topicName=GM-CSF单抗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=50fa30912176, createdName=diushouji, createdTime=Sun Aug 30 19:56:39 CST 2020, time=2020-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1940438, encodeId=7ff9194043854, content=<a href='/topic/show?id=0de4919efc' target=_blank style='color:#2F92EE;'>#human#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9197, encryptionId=0de4919efc, topicName=human)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=674961, createdName=tamgche, createdTime=Wed Oct 28 21:56:39 CST 2020, time=2020-10-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1912318, encodeId=2b241912318d4, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11204, encryptionId=4de7112046c, topicName=mAb)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Sun Dec 06 09:56:39 CST 2020, time=2020-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1283645, encodeId=7a5c1283645cf, content=<a href='/topic/show?id=2c00e784416' target=_blank style='color:#2F92EE;'>#细胞因子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77844, encryptionId=2c00e784416, topicName=细胞因子)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0ad8182, createdName=axin009, createdTime=Thu Mar 12 02:56:39 CST 2020, time=2020-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1426395, encodeId=f3b21426395e4, content=<a href='/topic/show?id=032b948ec5' target=_blank style='color:#2F92EE;'>#IgE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9487, encryptionId=032b948ec5, topicName=IgE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0cff4064659, createdName=zhenjiu124, createdTime=Thu Mar 12 02:56:39 CST 2020, time=2020-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1027389, encodeId=7352102e38930, content=新冠肺炎,疫情何时才能消失, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=公卫新人, createdTime=Tue Mar 10 14:56:39 CST 2020, time=2020-03-10, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1668865, encodeId=bcf9166886515, content=<a href='/topic/show?id=a41d5339c1' target=_blank style='color:#2F92EE;'>#CSF#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5339, encryptionId=a41d5339c1, topicName=CSF)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7a5226466702, createdName=kcb078, createdTime=Sun Nov 01 00:56:39 CST 2020, time=2020-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1809611, encodeId=28821809611aa, content=<a href='/topic/show?id=6cd683e603b' target=_blank style='color:#2F92EE;'>#胞因子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83760, encryptionId=6cd683e603b, topicName=胞因子)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/017ED6AFEB45F49165298113DDC0656A/100, createdBy=84182500174, createdName=ms7019579240139182, createdTime=Sat Jan 30 00:56:39 CST 2021, time=2021-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1704968, encodeId=a89c1e04968e3, content=<a href='/topic/show?id=7af98121ae' target=_blank style='color:#2F92EE;'>#GM-CSF单抗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8121, encryptionId=7af98121ae, topicName=GM-CSF单抗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=50fa30912176, createdName=diushouji, createdTime=Sun Aug 30 19:56:39 CST 2020, time=2020-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1940438, encodeId=7ff9194043854, content=<a href='/topic/show?id=0de4919efc' target=_blank style='color:#2F92EE;'>#human#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9197, encryptionId=0de4919efc, topicName=human)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=674961, createdName=tamgche, createdTime=Wed Oct 28 21:56:39 CST 2020, time=2020-10-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1912318, encodeId=2b241912318d4, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11204, encryptionId=4de7112046c, topicName=mAb)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Sun Dec 06 09:56:39 CST 2020, time=2020-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1283645, encodeId=7a5c1283645cf, content=<a href='/topic/show?id=2c00e784416' target=_blank style='color:#2F92EE;'>#细胞因子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77844, encryptionId=2c00e784416, topicName=细胞因子)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0ad8182, createdName=axin009, createdTime=Thu Mar 12 02:56:39 CST 2020, time=2020-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1426395, encodeId=f3b21426395e4, content=<a href='/topic/show?id=032b948ec5' target=_blank style='color:#2F92EE;'>#IgE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9487, encryptionId=032b948ec5, topicName=IgE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0cff4064659, createdName=zhenjiu124, createdTime=Thu Mar 12 02:56:39 CST 2020, time=2020-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1027389, encodeId=7352102e38930, content=新冠肺炎,疫情何时才能消失, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=公卫新人, createdTime=Tue Mar 10 14:56:39 CST 2020, time=2020-03-10, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1668865, encodeId=bcf9166886515, content=<a href='/topic/show?id=a41d5339c1' target=_blank style='color:#2F92EE;'>#CSF#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5339, encryptionId=a41d5339c1, topicName=CSF)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7a5226466702, createdName=kcb078, createdTime=Sun Nov 01 00:56:39 CST 2020, time=2020-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1809611, encodeId=28821809611aa, content=<a href='/topic/show?id=6cd683e603b' target=_blank style='color:#2F92EE;'>#胞因子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83760, encryptionId=6cd683e603b, topicName=胞因子)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/017ED6AFEB45F49165298113DDC0656A/100, createdBy=84182500174, createdName=ms7019579240139182, createdTime=Sat Jan 30 00:56:39 CST 2021, time=2021-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1704968, encodeId=a89c1e04968e3, content=<a href='/topic/show?id=7af98121ae' target=_blank style='color:#2F92EE;'>#GM-CSF单抗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8121, encryptionId=7af98121ae, topicName=GM-CSF单抗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=50fa30912176, createdName=diushouji, createdTime=Sun Aug 30 19:56:39 CST 2020, time=2020-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1940438, encodeId=7ff9194043854, content=<a href='/topic/show?id=0de4919efc' target=_blank style='color:#2F92EE;'>#human#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9197, encryptionId=0de4919efc, topicName=human)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=674961, createdName=tamgche, createdTime=Wed Oct 28 21:56:39 CST 2020, time=2020-10-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1912318, encodeId=2b241912318d4, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11204, encryptionId=4de7112046c, topicName=mAb)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Sun Dec 06 09:56:39 CST 2020, time=2020-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1283645, encodeId=7a5c1283645cf, content=<a href='/topic/show?id=2c00e784416' target=_blank style='color:#2F92EE;'>#细胞因子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77844, encryptionId=2c00e784416, topicName=细胞因子)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0ad8182, createdName=axin009, createdTime=Thu Mar 12 02:56:39 CST 2020, time=2020-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1426395, encodeId=f3b21426395e4, content=<a href='/topic/show?id=032b948ec5' target=_blank style='color:#2F92EE;'>#IgE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9487, encryptionId=032b948ec5, topicName=IgE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0cff4064659, createdName=zhenjiu124, createdTime=Thu Mar 12 02:56:39 CST 2020, time=2020-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1027389, encodeId=7352102e38930, content=新冠肺炎,疫情何时才能消失, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=公卫新人, createdTime=Tue Mar 10 14:56:39 CST 2020, time=2020-03-10, status=1, ipAttribution=)]
    2020-10-28 tamgche
  5. [GetPortalCommentsPageByObjectIdResponse(id=1668865, encodeId=bcf9166886515, content=<a href='/topic/show?id=a41d5339c1' target=_blank style='color:#2F92EE;'>#CSF#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5339, encryptionId=a41d5339c1, topicName=CSF)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7a5226466702, createdName=kcb078, createdTime=Sun Nov 01 00:56:39 CST 2020, time=2020-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1809611, encodeId=28821809611aa, content=<a href='/topic/show?id=6cd683e603b' target=_blank style='color:#2F92EE;'>#胞因子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83760, encryptionId=6cd683e603b, topicName=胞因子)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/017ED6AFEB45F49165298113DDC0656A/100, createdBy=84182500174, createdName=ms7019579240139182, createdTime=Sat Jan 30 00:56:39 CST 2021, time=2021-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1704968, encodeId=a89c1e04968e3, content=<a href='/topic/show?id=7af98121ae' target=_blank style='color:#2F92EE;'>#GM-CSF单抗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8121, encryptionId=7af98121ae, topicName=GM-CSF单抗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=50fa30912176, createdName=diushouji, createdTime=Sun Aug 30 19:56:39 CST 2020, time=2020-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1940438, encodeId=7ff9194043854, content=<a href='/topic/show?id=0de4919efc' target=_blank style='color:#2F92EE;'>#human#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9197, encryptionId=0de4919efc, topicName=human)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=674961, createdName=tamgche, createdTime=Wed Oct 28 21:56:39 CST 2020, time=2020-10-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1912318, encodeId=2b241912318d4, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11204, encryptionId=4de7112046c, topicName=mAb)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Sun Dec 06 09:56:39 CST 2020, time=2020-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1283645, encodeId=7a5c1283645cf, content=<a href='/topic/show?id=2c00e784416' target=_blank style='color:#2F92EE;'>#细胞因子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77844, encryptionId=2c00e784416, topicName=细胞因子)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0ad8182, createdName=axin009, createdTime=Thu Mar 12 02:56:39 CST 2020, time=2020-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1426395, encodeId=f3b21426395e4, content=<a href='/topic/show?id=032b948ec5' target=_blank style='color:#2F92EE;'>#IgE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9487, encryptionId=032b948ec5, topicName=IgE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0cff4064659, createdName=zhenjiu124, createdTime=Thu Mar 12 02:56:39 CST 2020, time=2020-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1027389, encodeId=7352102e38930, content=新冠肺炎,疫情何时才能消失, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=公卫新人, createdTime=Tue Mar 10 14:56:39 CST 2020, time=2020-03-10, status=1, ipAttribution=)]
    2020-12-06 snf701207
  6. [GetPortalCommentsPageByObjectIdResponse(id=1668865, encodeId=bcf9166886515, content=<a href='/topic/show?id=a41d5339c1' target=_blank style='color:#2F92EE;'>#CSF#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5339, encryptionId=a41d5339c1, topicName=CSF)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7a5226466702, createdName=kcb078, createdTime=Sun Nov 01 00:56:39 CST 2020, time=2020-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1809611, encodeId=28821809611aa, content=<a href='/topic/show?id=6cd683e603b' target=_blank style='color:#2F92EE;'>#胞因子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83760, encryptionId=6cd683e603b, topicName=胞因子)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/017ED6AFEB45F49165298113DDC0656A/100, createdBy=84182500174, createdName=ms7019579240139182, createdTime=Sat Jan 30 00:56:39 CST 2021, time=2021-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1704968, encodeId=a89c1e04968e3, content=<a href='/topic/show?id=7af98121ae' target=_blank style='color:#2F92EE;'>#GM-CSF单抗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8121, encryptionId=7af98121ae, topicName=GM-CSF单抗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=50fa30912176, createdName=diushouji, createdTime=Sun Aug 30 19:56:39 CST 2020, time=2020-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1940438, encodeId=7ff9194043854, content=<a href='/topic/show?id=0de4919efc' target=_blank style='color:#2F92EE;'>#human#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9197, encryptionId=0de4919efc, topicName=human)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=674961, createdName=tamgche, createdTime=Wed Oct 28 21:56:39 CST 2020, time=2020-10-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1912318, encodeId=2b241912318d4, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11204, encryptionId=4de7112046c, topicName=mAb)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Sun Dec 06 09:56:39 CST 2020, time=2020-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1283645, encodeId=7a5c1283645cf, content=<a href='/topic/show?id=2c00e784416' target=_blank style='color:#2F92EE;'>#细胞因子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77844, encryptionId=2c00e784416, topicName=细胞因子)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0ad8182, createdName=axin009, createdTime=Thu Mar 12 02:56:39 CST 2020, time=2020-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1426395, encodeId=f3b21426395e4, content=<a href='/topic/show?id=032b948ec5' target=_blank style='color:#2F92EE;'>#IgE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9487, encryptionId=032b948ec5, topicName=IgE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0cff4064659, createdName=zhenjiu124, createdTime=Thu Mar 12 02:56:39 CST 2020, time=2020-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1027389, encodeId=7352102e38930, content=新冠肺炎,疫情何时才能消失, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=公卫新人, createdTime=Tue Mar 10 14:56:39 CST 2020, time=2020-03-10, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=1668865, encodeId=bcf9166886515, content=<a href='/topic/show?id=a41d5339c1' target=_blank style='color:#2F92EE;'>#CSF#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5339, encryptionId=a41d5339c1, topicName=CSF)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7a5226466702, createdName=kcb078, createdTime=Sun Nov 01 00:56:39 CST 2020, time=2020-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1809611, encodeId=28821809611aa, content=<a href='/topic/show?id=6cd683e603b' target=_blank style='color:#2F92EE;'>#胞因子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83760, encryptionId=6cd683e603b, topicName=胞因子)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/017ED6AFEB45F49165298113DDC0656A/100, createdBy=84182500174, createdName=ms7019579240139182, createdTime=Sat Jan 30 00:56:39 CST 2021, time=2021-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1704968, encodeId=a89c1e04968e3, content=<a href='/topic/show?id=7af98121ae' target=_blank style='color:#2F92EE;'>#GM-CSF单抗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8121, encryptionId=7af98121ae, topicName=GM-CSF单抗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=50fa30912176, createdName=diushouji, createdTime=Sun Aug 30 19:56:39 CST 2020, time=2020-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1940438, encodeId=7ff9194043854, content=<a href='/topic/show?id=0de4919efc' target=_blank style='color:#2F92EE;'>#human#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9197, encryptionId=0de4919efc, topicName=human)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=674961, createdName=tamgche, createdTime=Wed Oct 28 21:56:39 CST 2020, time=2020-10-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1912318, encodeId=2b241912318d4, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11204, encryptionId=4de7112046c, topicName=mAb)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Sun Dec 06 09:56:39 CST 2020, time=2020-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1283645, encodeId=7a5c1283645cf, content=<a href='/topic/show?id=2c00e784416' target=_blank style='color:#2F92EE;'>#细胞因子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77844, encryptionId=2c00e784416, topicName=细胞因子)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0ad8182, createdName=axin009, createdTime=Thu Mar 12 02:56:39 CST 2020, time=2020-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1426395, encodeId=f3b21426395e4, content=<a href='/topic/show?id=032b948ec5' target=_blank style='color:#2F92EE;'>#IgE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9487, encryptionId=032b948ec5, topicName=IgE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0cff4064659, createdName=zhenjiu124, createdTime=Thu Mar 12 02:56:39 CST 2020, time=2020-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1027389, encodeId=7352102e38930, content=新冠肺炎,疫情何时才能消失, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=公卫新人, createdTime=Tue Mar 10 14:56:39 CST 2020, time=2020-03-10, status=1, ipAttribution=)]
    2020-03-12 zhenjiu124
  8. [GetPortalCommentsPageByObjectIdResponse(id=1668865, encodeId=bcf9166886515, content=<a href='/topic/show?id=a41d5339c1' target=_blank style='color:#2F92EE;'>#CSF#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5339, encryptionId=a41d5339c1, topicName=CSF)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7a5226466702, createdName=kcb078, createdTime=Sun Nov 01 00:56:39 CST 2020, time=2020-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1809611, encodeId=28821809611aa, content=<a href='/topic/show?id=6cd683e603b' target=_blank style='color:#2F92EE;'>#胞因子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83760, encryptionId=6cd683e603b, topicName=胞因子)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/017ED6AFEB45F49165298113DDC0656A/100, createdBy=84182500174, createdName=ms7019579240139182, createdTime=Sat Jan 30 00:56:39 CST 2021, time=2021-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1704968, encodeId=a89c1e04968e3, content=<a href='/topic/show?id=7af98121ae' target=_blank style='color:#2F92EE;'>#GM-CSF单抗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8121, encryptionId=7af98121ae, topicName=GM-CSF单抗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=50fa30912176, createdName=diushouji, createdTime=Sun Aug 30 19:56:39 CST 2020, time=2020-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1940438, encodeId=7ff9194043854, content=<a href='/topic/show?id=0de4919efc' target=_blank style='color:#2F92EE;'>#human#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9197, encryptionId=0de4919efc, topicName=human)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=674961, createdName=tamgche, createdTime=Wed Oct 28 21:56:39 CST 2020, time=2020-10-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1912318, encodeId=2b241912318d4, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11204, encryptionId=4de7112046c, topicName=mAb)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Sun Dec 06 09:56:39 CST 2020, time=2020-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1283645, encodeId=7a5c1283645cf, content=<a href='/topic/show?id=2c00e784416' target=_blank style='color:#2F92EE;'>#细胞因子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77844, encryptionId=2c00e784416, topicName=细胞因子)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0ad8182, createdName=axin009, createdTime=Thu Mar 12 02:56:39 CST 2020, time=2020-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1426395, encodeId=f3b21426395e4, content=<a href='/topic/show?id=032b948ec5' target=_blank style='color:#2F92EE;'>#IgE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9487, encryptionId=032b948ec5, topicName=IgE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0cff4064659, createdName=zhenjiu124, createdTime=Thu Mar 12 02:56:39 CST 2020, time=2020-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1027389, encodeId=7352102e38930, content=新冠肺炎,疫情何时才能消失, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=公卫新人, createdTime=Tue Mar 10 14:56:39 CST 2020, time=2020-03-10, status=1, ipAttribution=)]
    2020-03-10 公卫新人

    新冠肺炎,疫情何时才能消失

    0

相关资讯

新型冠状病毒临床细胞因子风暴的特点、影像学特征

细胞因子风暴综合征(Cytokine Storm Syndrome,CSS)细胞因子风暴综合征最早1952年被Farquhar和Claireaux在家族性噬血细胞淋巴组织细胞增生症(fHLH)描述。在之后的五十年里研究并不多。直到2002年SARS开始,CSS引起多器官功能不全(MOF),导致极高的致死率,才再次引起了广泛关注。之后H7N9,H5N1,包括最近的2019-nCov,都有不同程度的C

ChinaXiv:干细胞移植:显著改善「新冠」重症患者预后,有效规避「细胞因子风暴」

导读:2020年3月伊始,持续一个多月的抗疫攻坚战迎来了新的胜利:全国新冠肺炎确诊病例除湖北省外连续三天个位数增长,这与一线医护和广大人民的顽强努力密不可分。然而,目前我国新冠肺炎重症患者尚有7365名,如何尽快改善重症患者的预后、进一步降低死亡率,将是现阶段的重点问题。